(2-trifluoroacetyl-1,2,3,4-tetrahydro-6-isoquinolinyl)sulfonyl chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (2-trifluoroacetyl-1,2,3,4-tetrahydro-6-isoquinolinyl)sulfonyl chloride
• 英文别名: 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonyl chloride；2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-6-sulphonyl chloride；2-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonyl chloride；2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinoline-6-sulfonyl chloride
• 化学式: C₁₁H₉ClF₃NO₃S
• 分子量: 327.712
• InChiKey: XYIKTLMPVJQPCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2-trifluoroacetyl-1,2,3,4-tetrahydro-6-isoquinolinyl)sulfonyl chloride 在 吡啶 、 4-二甲氨基吡啶 、 水 、 potassium hydroxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 32.0h， 生成 N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
  参考文献：
  名称：

  Identification of 2-[2-(4- tert -butylphenyl)ethyl]- N -(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide ( 29 ) as an orally available MGAT2 inhibitor

  摘要：

  MGAT2 (monoacylglycerol acyltransferase 2) is expected to be an attractive target for the drug treatment of obesity, diabetes, and other disease. We describe our exploration and structure-activity relationship (SAR) study of 2,3-dihydro-1H-isoindole-5-sulfonamide derivatives. In this study, we identified 29 as an orally available inhibitor of MGAT2 through optimization especially in terms of solubility. This compound exhibited moderate potency in the enzyme inhibitory assay (IC50 = 1522 nM) and significant suppression of fat absorption (57% inhibition) in mice oral lipid tolerance test. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.06.065
• 作为产物：
  描述：

  四氢异喹啉 在 吡啶 、 氯磺酸 、 4-二甲氨基吡啶 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 (2-trifluoroacetyl-1,2,3,4-tetrahydro-6-isoquinolinyl)sulfonyl chloride
  参考文献：
  名称：

  Identification of 2-[2-(4- tert -butylphenyl)ethyl]- N -(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide ( 29 ) as an orally available MGAT2 inhibitor

  摘要：

  MGAT2 (monoacylglycerol acyltransferase 2) is expected to be an attractive target for the drug treatment of obesity, diabetes, and other disease. We describe our exploration and structure-activity relationship (SAR) study of 2,3-dihydro-1H-isoindole-5-sulfonamide derivatives. In this study, we identified 29 as an orally available inhibitor of MGAT2 through optimization especially in terms of solubility. This compound exhibited moderate potency in the enzyme inhibitory assay (IC50 = 1522 nM) and significant suppression of fat absorption (57% inhibition) in mice oral lipid tolerance test. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.06.065

文献信息

• Parallel Solution-Phase Synthesis and General Biological Activity of a Uridine Antibiotic Analog Library
  作者：Omar Moukha-chafiq、Robert C. Reynolds

  DOI：10.1021/co4001452

  日期：2014.5.12

  coupling of the amino terminus of d-phenylalanine methyl ester to the free 5′-carboxylic acid moiety of 33 followed by sodium hydroxide treatment led to carboxylic acid analog 77. Hydrolysis of this material gave analog 78. The intermediate 77 served as the precursor for the preparation of novel dipeptidyl uridine analogs 79–99 through peptide coupling reactions to diverse amine reactants. None of the described

  在 NIH 路线图计划的中试规模库 (PSL) 计划下，以溶液相方式从胺2和羧酸33和77合成了一个包含 94 种尿苷抗生素类似物的小型库。多样醛，磺酰氯，和羧酸反应物套缩合，2，酸介导的水解导致后，向目标化合物3 - 32以良好的收率和高的纯度。同样，用不同的胺和磺胺处理33得到34 – 75。d氨基末端的偶联-苯丙氨酸甲酯到33的游离 5'-羧酸部分，然后用氢氧化钠处理产生羧酸类似物77。该材料的水解得到类似物78。中间77担任该前体为二肽基新颖尿苷类似物的制备79 - 99通过肽偶联到不同的胺反应剂反应。所描述的化合物均未显示出显着的抗癌或抗疟活性。通过 NIH MLPCN 计划提供和报告的初级筛选中的酶和受体，许多样品表现出各种有希望的抑制性、激动剂、拮抗剂或激活剂特性。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE NLRP
  申请人：IFM TRE INC

  公开号：WO2019023147A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一方面，特征在于公式AA的化合物，或其药用可接受的盐。公式AA中所示的变量如权利要求中所定义。公式AA的化合物是NLRP3活性的调节剂，因此，可用于治疗代谢紊乱（例如2型糖尿病、动脉硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩侧索硬化症或帕金森病）、肺病（例如哮喘、慢性阻塞性肺病或特发性肺纤维化）、肝病（例如非酒精性脂肪肝炎、病毒性肝炎或肝硬化）、胰腺病（例如急性胰腺炎或慢性胰腺炎）、肾病（例如急性肾损伤或慢性肾损伤）、肠病（例如克罗恩病或溃疡性结肠炎）、皮肤病（例如银屑病）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨石化病）、眼病（例如青光眼或黄斑变性）、由病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。
• [EN] ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES<br/>[FR] DERIVES ANTITHROMBOTIQUES D'AMIDINOPHENYLALANINE ET D'AMIDINOPYRIDYLALANINE
  申请人：PFIZER LIMITED

  公开号：WO1995013274A1

  公开（公告）日：1995-05-18

  (EN) Compounds of formula (I), pharmaceutically acceptable salt thereof, and pharmaceutically acceptable solvates of either entity, wherein X is CH or N; Y is optionally monounsaturated C3-C5 alkylene optionally substituted with C1-C4 alkyl or methylene; R1 is H; C1-C4 alkyl optionally substituted with C1-C4 alkoxy, OH, NR5R6, CONR5R6, C3-C6 cycloalkyl or aryl; or C3-C6 alkenyl; R2 is H; C1-C4 alkyl optionally substituted with C1-C4 alkoxy, OH, NR5R6, CONR5R6, C3-C6 cycloalkyl or aryl; or CONR5R6; R3 and R4 are each independently selected from H; C1-C4 alkyl optionally substituted with NR5R6; C1-C4 alkoxy; halo; CONR5R6 and aryl; R5 and R6 are each independently selected from H and C1-C4 alkyl; and m and n are each independently 1, 2 or 3; are potent and selective thrombin inhibitors useful in the treatment of, inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.(FR) Composés répondant à la formule (I), leur sel pharmaceutiquement acceptable, et les solvates pharmaceutiquement acceptables de l'une ou l'autre de ces entités. Dans ladite formule, X représente CH ou N; Y représente alkylène C3-5 éventuellement monoinsaturé éventuellement substitué par alkyle C1-4 ou méthylène; R1 représente H, alkyle C1-4 éventuellement substitué par alcoxy C1-4, OH, NR5R6, CONR5R6, cycloalkyle C3-6 ou aryle, ou alcényle C3-6; R2 représente H, alkyle C1-4 éventuellement substitué par alcoxy C1-4, OH, NR5R6, CONR5R6, cycloalkyle C3-6 ou aryle, ou CONR5R6; R3 et R4, indépendamment l'un de l'autre, représentent H, alkyle C1-4 éventuellement substitué par NR5R6, alcoxy C1-4, halo, CONR5R6 ou aryle; R5 et R6, indépendamment l'un de l'autre, représentent H ou alkyle C1-4; et m et n, indépendamment l'un de l'autre, valent 1, 2 ou 3. Ces composés sont des inhibiteurs puissants et sélectifs de la thrombine utilisables dans le traitement, entre autres, de la thrombose veineuse profonde, de la réocclusion suivant un traitement thrombolytique, de l'obstruction artérielle chronique, des maladies vasculaires périphériques, de l'infarctus du myocarde aigu, de l'angor instable, de la fibrillation auriculaire, des accès thrombotiques, des accidents ischémiques transitoires, de la resténose et de l'occlusion suivant l'angioplastie, ou des troubles neurodégénératifs.

  (I)式化合物、其药学上可接受的盐和任一实体的药学上可接受的溶剂，其中X为CH或N; Y为可选的单不饱和C3-C5烷基，可选地取代C1-C4烷基或亚甲基; R1为H; C1-C4烷基，可选地取代C1-C4烷氧基、OH、NR5R6、CONR5R6、C3-C6环烷基或芳基; 或C3-C6烯基; R2为H; C1-C4烷基，可选地取代C1-C4烷氧基、OH、NR5R6、CONR5R6、C3-C6环烷基或芳基; 或CONR5R6; R3和R4各自独立地选自H; C1-C4烷基，可选地取代NR5R6; C1-C4烷氧基; 卤素; CONR5R6和芳基; R5和R6各自独立地选自H和C1-C4烷基; m和n各自独立地为1、2或3; 是有效且选择性的凝血酶抑制剂，用于治疗深静脉血栓形成，溶栓治疗后的再闭塞，慢性动脉阻塞，周围血管疾病，急性心肌梗死，不稳定性心绞痛，心房颤动，血栓性中风，短暂性脑缺血发作，血管成形术后的再狭窄和闭塞，或神经退行性疾病的治疗中。
• Heterocyclic derivatives and their use as antithrombotic agents
  申请人：——

  公开号：US20030130270A1

  公开（公告）日：2003-07-10

  The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is 0 or S; X′ being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents. 1

  本发明涉及抗血栓化合物，包括具有公式（I）的Q基团，其中亚结构（i）是从（a、b和c）中选择的结构，其中X为0或S；X'独立地为CH或N；m为0、1、2或3；其中Q基团通过氧原子或可选择取代的氮或碳原子结合，或其药学上可接受的盐或前药。本发明的化合物具有治疗活性，特别是抗血栓剂。
• Compounds and compositions for treating conditions associated with NLRP activity
  申请人：NOVARTIS INFLAMMASOME RESEARCH, INC.

  公开号：US10654816B2

  公开（公告）日：2020-05-19

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

  在一个方面，式 AA 的化合物或其药学上可接受的盐是其特征： 或其药学上可接受的盐，其中式 A 中所示的变量可以如本文中任何地方所定义的那样。